Oryzon Genomics S.A. (LON: 0RDB)

Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of GBP 77.16 million. The enterprise value is 83.84 million.

Market Cap	77.16M
Enterprise Value	83.84M

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+8.99%
Shares Change (QoQ)	+0.70%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	54.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-24.67
EV / Sales	7.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.02

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	256,728
Profits Per Employee	-73,890
Employee Count	46
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.76% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-24.76%
50-Day Moving Average	1.53
200-Day Moving Average	1.78
Relative Strength Index (RSI)	40.38
Average Volume (20 Days)	876

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of GBP 11.81 million and -3.40 million in losses. Loss per share was -0.05.

Revenue	11.81M
Gross Profit	11.61M
Operating Income	-34,155
Pretax Income	-5.69M
Net Income	-3.40M
EBITDA	68,532
EBIT	-34,155
Loss Per Share	-0.05

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 98.28%, with operating and profit margins of -0.29% and -28.78%.

Gross Margin	98.28%
Operating Margin	-0.29%
Pretax Margin	-48.17%
Profit Margin	-28.78%
EBITDA Margin	0.58%
EBIT Margin	-0.29%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.99%
Shareholder Yield	-8.99%
Earnings Yield	-4.40%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a